Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative low-molecular-weight heparin in elderly unstable intertrochanteric fractures
ChiCTR2200066819Phase 4Not yet recruiting
- Sponsor
- Hengyang Central Hospital
- Start
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of low molecular weight heparin calcium in intertrochanteric fracture and venous thromboembolism (VTE) (2 arms), sponsored by Hengyang Central Hospital. Primary endpoints: VTE incidence and Total perioperative blood loss. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
low molecular weight heparin calcium
03
Conditions
intertrochanteric fracturevenous thromboembolism (VTE)
Beyond the preview
Go deeper on ChiCTR2200066819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066819.